Adult onset Still’s disease – a case report
Authors:
M. Skácelová; P. Horák
Authors‘ workplace:
III. interní klinika – nefrologická, revmatologická a endokrinologická FN a LF UP Olomouc
Published in:
Čes. Revmatol., 20, 2012, No. 4, p. 198-202.
Category:
Case Report
Overview
Adult onset Still’s disease (AODS) is an autoinflammatory disease with variety of clinical features, such as fever, arthritis, skin rash, lymfadenopathy, hepatosplenomegaly etc. Differential diagnosis is difficult and based on exclusion of infectious, tumorous or autoimmune diseases. In therapy glucocorticoids are used, if there is lack of effect, DMARDs or biologic therapy are used.
Key words:
Adult onset Still’s disease, fever of unknown etiology, glucocorticoids, biologic therapy, anakinra
Sources
1. Jean YK. et al. Spectrum of lymph node pathology in adult onset Stillęs disease, J. Clin Pathol, 2004:1052-1056
2. Ohta A, Yamaguchi M, Tsunematsu T, et al. Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol 1990; 17:1058.
3. Colebunders R, Stevens WJ, Vanagt E, Snoeck J. Adult Still’s disease caused by Yersinia enterocolitica infection. Arch Intern Med 1984; 144:1880.
4. Sampalis JS, Medsger TA Jr, Fries JF, et al. Risk factors for adult Still’s disease. J Rheumatol 1996; 23:2049
5. Yokota S, Miyamae T, Imagawa T, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005; 28:231.
6. Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 2010; 87:483.
7. Šedivá A, Slíva J, Doležalová P, Skácelová M. Anakinra. Farmakoterapie 2011; 7(6): 621-629
8. Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 2005; 52:1794.
9. Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007; 66:842.
10. Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007; 37:189.
11. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis 2005; 64:647.
12. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009; 36:1078.
13. Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refraktory adult onset Still’s disease with rituximab. Ann Rhem Dis 20006; 65:1117
14. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63:465.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2012 Issue 4
Most read in this issue
- Adult onset Still’s disease – a case report
- Osteoimmunology
- Genes of major histocompatibility complex are not only transplantation antigens
- Abatacept and its use for the treatment of rheumatoid arthritis in the Czech Republic – data from the ATTRA registry